Managing locally advanced bladder cancer

References

• Abol-Enein H, El Makresh M, El Baz M, Ghoneim M. Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomized study. Br. J. Ural 80, 49 (1997).
   Google Scholar
• Bassi P, Pappagallo GL, Sperandio P et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: results of a multicenter Phase III trial." Ural 161 (Suppl. 4), 264 (1999).
   Google Scholar
• Bochner BH, Herr FIW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens.' Urol. 166(6), 2295–2296 (2001).
   PubMed Web of Science ®Google Scholar
• Bono AM Benvenuti C, Reali Let al Adjuvant chemotherapy in advanced bladder cancer. Italian Um-Oncologic Co-operative Group. Prog. Gun. Biol. Res. 303, 533–540 (1989).
   PubMedGoogle Scholar
• Cooke PW, Dunn JA, Latief T, Bathers S, James ND, Wallace DM. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur. Ural 38(3), 279–286 (2000).
   PubMedGoogle Scholar
• Crawford ED, Natale RB, Burton H. Southwest Oncology Group Study 8710: trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080). Frog. Biol. Res. 353,111-113 (1990).
   Google Scholar
• Dreicer R Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer. Semin. Ural Oncol 19(3), 180–185 (2001).
   PubMedGoogle Scholar
• Droz J-P, Fizazi K, Beuzeboc P et al. Gemcitabine and cisplatin as adjuvant chemotherapy for locally advanced bladder cancer after cystectomy: preliminary results of a feasibility study. Proc. Am. Soc. (lin. °neat (2002) (Abstract 2425).
   Google Scholar
• Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 312(25), 1604–1608 (1985).
   Google Scholar
• •Basic article on the phenomenon of stage migration.
   Google Scholar
• Fossa SD, Waehre H, Aass N, Jacobsen AB, Olsen DR, Ous S. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 72(10), 3036–3043 (1993).
   Google Scholar
• Freiha F, Reese J, Toni FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and 495–499 (1996).
   Google Scholar
• •Third randomized trial in favor of adjuvant chemotherapy.
   Google Scholar
• Gschwend JE, Vieweg J, Fair WR Early vs. delayed cystectomy for invasive bladder cancer – impact on disease specific survival. J. Urol. 157 (Suppl. 4), 385 (1997).
   Google Scholar
• Hall RR. Updated results of a randomised controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 710).
   Google Scholar
• Hautmann RE, Paiss T, Kleinschmidt K, de Petriconi R Impact of early cystectomy on survival in bladder cancer patients. J. Ural 157\(Suppl. 4), 374 (1997).
   Google Scholar
• Horwich A, Pendlebury S, Dearnaley D. Organ conservation in bladder cancer. Eur. J. Cancer 31\(Suppl. 5), 208 (1995).
   Google Scholar
• International collaboration of trialists.
   Google Scholar
• •Largest neoadjuvant study for muscle-invasive bladder cancer reported. Later
   Google Scholar
• Khaled HM, Zaghloul MS, Ghoneim M et al. A randomized Phase III study of neoadjuvant chemotherapy for invasive bladder cancer with gemcitabine and cisplatin. Proc. Am. Soc. (lin. °neat (2002) (Abstract 2421). Leissner J, Hohenfellner R, Thuroff JW, Wolf HK Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85(7), 817–823 (2000). Important paper on the topic of extended versus limited regional lymphnode dissection Loehrer PJ Sr, Einhom LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study." (lin. Oncol 10(7), 1066–1073 (1992). Supports the role of MVAC as 'gold standard' during the early 1990s. Logothetis CJ, Dexeus FH, Finn Let al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. (lin. Oncol 8(6), 1050–1055 (1990). Supports the role of MVAC as 'gold standard' during the early 1990s. Logothetis CJ, Johnson DE, Chong C et al. Adjuvant cyclophospharnide, doxorubicin and cisplatin chemotherapy for bladder cancer: an update.' (lin. °neat 6(10), 1590–1596 (1988). Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Co-operative Bladder Cancer Study Group. J. Urol. 155(6), 1903–1906 (1996).
   Google Scholar
• Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU. Int. 85(7), 817–823 (2000).
   PubMed Web of Science ®Google Scholar
• •Important paper on the topic of extended versus limited regional lymphnode dissection
   Google Scholar
• Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10(7), 1066–1073 (1992).
   Google Scholar
• •Supports the role of MVAC as ‘gold Standard’ during the early 1990s.
   Google Scholar
• Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8(6), 1050–1055 (1990).
   Google Scholar
• •Supports the role of MVAC as ‘gold standard’ during the early 1990s.
   Google Scholar
• Logothetis CJ, Johnson DE, Chong C et al. Adjuvant cyclophosphamide, doxorubicin and cisplatin chemotherapy for bladder cancer: an update. J. Clin. Oncol. 6(10), 1590–1596 (1988).
   Google Scholar
• Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Co-operative Bladder Cancer Study Group. J. Urol. 155(6), 1903–1906 (1996).
   Google Scholar
• Martinez-Pineiro JA, Gonzalez MM, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized Phase III study." Ural 153(3 Pt 2), 964–973 (1995).
   Google Scholar
• Manus P, Birkenhake S, Sauer R The age correction of survival probabilities in cancer studies. Strahlenther. Onkol. 174(1), 1–6 (1998).
   Google Scholar
• Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39\(Suppl. 2), 973–980 (1977).
   Google Scholar
• Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. j Clin. °neat 19(20), 4005–4013 (2001).
   Google Scholar
• •The only randomized trial systematically including adjuvant and neoadjuvant adjunctive chemotherapy to cystectomy.
   Google Scholar
• Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymphnode metastases from bladder Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60(1), 62–67 (2002). Cancer outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy." Ural. 166(1), 19–23 (2001).
   Google Scholar
• Montie JE Against bladder sparing surgery.' Ural. 162(2), 452–455 (1999).
   Google Scholar
• Natale RB, Grossman HB, Blumenstein B et al. Randomized Phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc. Am. Soc. Oncol. (2001) (Abstract 3).
   Google Scholar
• •Most iment Phase III trial supporting neoadjuvant chemotherapy prior to cystectomy (only published as abstract yet, but slide presentation downloadable at www.conference-castcotn/asco/vm 192001/ lectures/ frarne.asp?dir.Natale&slide.018cmax.27)
   Google Scholar
• Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymphnode dissection improves survival for patients with bladder cancer confined to the bladder wall." UroZ 160(6 Pt 1), 2015-2019 (1998).
   Google Scholar
• •Important paper on the topic of extended versus limited regional lymphnode dissection.
   Google Scholar
• Retz M, Lehmann J, Szysnik C et al. Detection of occult micrometastasis in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR Urologe A 41(Suppl. 1), 68 (2002).
   Google Scholar
• Retz M, Lehmann J, Trocha Get id Long- term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma. Cancer 89(5), 245–250 (2000).
   Google Scholar
• Riibben H, Otto T. Locally advanced or metastazised carcinoma of the urinary bladder: current aspects of therapy. Urologe A 40,464 467 (2001).
   Google Scholar
• Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int. J Radiat. Oncol. Biol. Phys. 40(1), 121–127 (1998).
   Google Scholar
• Sell A, Jakobson A, Nerstrom B. Treatment of advanced bladder cancer category T2, T3, T4a. Scan. J Ural. 1VephroZ 138(Suppl.), 193–201 (1991).
   Google Scholar
• Sherif A, Rintala E, Mestad O, Nilsson S, Malmstrom PU. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic cystectomy trial 2. J Ural. 167\(Suppl. 4), 262 (2002).
   Google Scholar
• Shipley WU, Kaufman DS, Zehr E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60(1), 62–67 (2002).
   Google Scholar
• Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Ural. 145(3), 459–464 (1991).
   Google Scholar
• •First randomized trial in favor of adjuvant chemotherapy.
   Google Scholar
• Stadler WM, Steinberg GS, Vogelzang NJ. Low rate of patient enrollment in an adjuvant study of gemcitabine, cisplatin and amifostine for high risk localized bladder cancer. Proc. Am. Soc. Clin. Oncol. 19,1409 (2000).
   Google Scholar
• Stein JP, Clark P, Miranda G, Groshen S, Lieskovsky G, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy. Ural. 167 (Suppl. 4), 284 (2002).
   Google Scholar
• Stein JP Lieskovsky G, Cote R et aZ Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.' Clin. OncoZ 19(3), 666–675 (2001).
   Google Scholar
• Sternberg CN, de Mulder PH, Schomagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus. classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. Clin. Oncol. 19(10), 2638–2646 (2001).
   Google Scholar
• Stemberg CN, Parmar MK. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.' Clin. Oncol. 19\(Suppl. 18), 21S-26S (2001).
   Google Scholar
• Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. j Ural. 133(3), 403–407 (1985).
   Google Scholar
• ••Marks the beginning of effective systemiccombination chemotherapy for urothelial carcinoma and its widespread use.
   Google Scholar
• Stöckle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study." Ural. 148(2 Pa), 302–306 (1992).
   Google Scholar
• •Second randomized trial in favor of adjuvant chemotherapy.
   Google Scholar
• Stöckle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.' Ural. 153(1), 47–52 (1995).
   Google Scholar
• Stöckle M, Wellek S, Meyenburg W et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48(6), 868–875 (1996).
   PubMedGoogle Scholar
• Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial." Ural. 152(1), 81–84 (1994).
   Google Scholar
• Sylvester R, Stemberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann. Oncol. 11(7), 851–856 (2000).
   PubMed Web of Science ®Google Scholar
• •Educational review on methodological flaws and statistical shortcomings encountered in reported Phase III studies on adjuvant chemotherapy for locally advanced bladder cancer.
   Google Scholar
• von der Maase H, Hansen SW, Roberts JT et aZ Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. Clin. Oncol. 18(17), 3068–3077 (2000).
   Google Scholar
• ••Largest Phase III chemotherapy trial inadvanced bladder cancer to date comparing gemcitabine/cisplatin with MVAC which has likely changed the course of systemic chemotherapy for bladder cancer not only for metastatic disease but also for adjunctive chemotherapy trials.
   Google Scholar
• Wishnow KI, Tenney DM. Will Rogers and the results of radical cystectomy for invasive bladder cancer. Ural. Clin. N Am. 18(3), 529–537 (1991).
   Google Scholar